OptiBiotix Health PLC Extension of territories for GoFigure(R) (2793H)
24 March 2020 - 6:00PM
UK Regulatory
TIDMOPTI
RNS Number : 2793H
OptiBiotix Health PLC
24 March 2020
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
Extension of territories for GoFigure(R)
with Extensor
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness
d e vel o ping co m p o u n ds to tack le o besit y, high choleste
r ol, diabetes and skincare, a nn o unces it has extended the
territories of its original distribution agreements with Extensor
Robert Buczek ("Extensor") to distribute OptiBiotix's own label
GoFigure(R) consumer weight management products in Ukraine,
Estonia, Lithuania, Latvia, Kazakhstan, Kyrgyzstan, Tajikistan,
Uzbekistan, Turkmenistan, Armenia, Azerbaijan, Georgia, Belarus,
Moldova and Russia.
Extensor is OptiBiotix's exclusive partner in Poland for
distributing its GoFigure(R) product range (RNS: 22 May 2019) and
SlimBiome(R) (RNS: 6 December 2019). The signing of an amendment to
the agreement granting Extensor exclusive rights to distribute
GoFigure(R) into additional territories highlights the positive
evolution of the GoFigure(R) and SlimBiome(R) distribution
agreements. The deal will create new commercial opportunities in
new territories which may generate revenues with the
commercialisation of the GoFigure(R) range on new online platforms
such as Domo in Ukraine:
https://domo.co.ua/search?string=Gofigure&category=all .
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics
division , c o mmented: "We are very pleased to strengthen our
partnership with Extensor to distribute our GoFigure(R) range
beyond the Polish borders as they have proven to be a very reliable
commercial partner and have recently placed additional orders for
GoFigure(R) branded products to replenish their stocks. The signing
of a territory extension amendment to the original agreement shows
a positive evolution of the relationship and increases the global
reach of our trademarks thus contributing to increasing the value
of our portfolio of trademarks."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
goetzpartners securities Limited Tel: 0203 859 7725
Ulrich Kinzel
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCBRGDXUGDDGGX
(END) Dow Jones Newswires
March 24, 2020 03:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024